Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Arpida plans public offering on the SWX Swiss Exchange initial


THIS IS A RESTRICTED COMMUNICATION AND YOU MAY NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON PROHIBITED BY THE LEGENDS CONTAINED HEREIN.


Muenchenstein / Basel, Switzerland, 11th April, 2005. Arpida Ltd., a Swiss anti-infectives company, announced today its intention to proceed with an Initial Public Offering (IPO) of shares and to seek a listing on the SWX Swiss Exchange. In connection with the proposed IPO, Deutsche Bank has been appointed Global Co-ordinator, Sole Bookrunner and Sole Lead Manager, Julius Baer, Lombard Odier Darier Hentsch, and swissfirst will act as Co-Lead Managers.

The IPO and listing are expected to complete in the next few months, subject to market conditions. Further details of the proposed offering will be announced at a later date.


About Arpida Ltd. (www.arpida.ch)
Arpida, a biopharmaceutical company based near Basel, is focused on the discovery and development of novel antibiotic drugs that seek to overcome the growing problem of bacterial resistance. Arpida uses an integrated multidisciplinary platform including genomics-assisted selection of novel antibacterial targets to develop its portfolio of potential drug candidates.

Arpida’s leading product candidate is injectable iclaprim, a broad-spectrum antibiotic that targets severe infections requiring hospital treatment, including those caused by MRSA (methicillin-resistant Staphylococcus aureus). In March 2005, Arpida received clearance from the FDA to conduct Phase III clinical trials for injectable iclaprim in the US as part of a global Phase III programme for the treatment of cSSSI (complicated skin and skin structure infections).

Iclaprim is also orally available and an oral formulation is currently in Phase I trials. Arpida believes oral iclaprim offers significant benefits as it would enable patients to be discharged from hospitals earlier by allowing them to continue and complete their treatment at home.

Arpida’s second most advanced antibiotic drug candidate, AR-709, targets severe respiratory tract and inner ear infections in the community setting. AR-709 is in late pre-clinical development. In addition, the company has a further 12 pre-clinical antibiotic programmes derived from its own discovery platform, which are at various stages of development.

Arpida has raised a total of CHF141 million (€91 million) from international venture capital, institutional and private investors since 1997. The company has research facilities near Basel, Switzerland and in Copenhagen, Denmark, and it currently employs 72 people.

Photos
Members of the media can go directly to the VisualMedia site and register their details through a simple one-off registration process. A password will be sent back within 10 minutes of receiving a registration.

High resolution images will be available for the media to view and download free of charge from www.vismedia.co.uk, from 9.00am today.

For further information please contact:
Arpida
Dr Khalid Islam, President and CEO
Harry Welten, MBA, CFO and Senior Vice President

Tel: + 41 61 417 96 60
Tel: + 41 61 417 96 65
Citigate Dewe Rogerson
David Dible / Mark Swallow/ Valerie Auffray Tel: +44 (0)207 638 9571
Tolxdorff & Eicher Consulting (Swiss enquiries)
Daniel Eicher Tel: +41 1 718 25 25


This press release contains specific forward-looking statements, e.g. statements including terms like 'believe', 'assume', 'expect' or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt t


Publisher Contact Information:

Arpida Ltd.
+ 41 61 417 96 60
-

Company profile of Arpida Ltd. (acquired by Evolva)
Past press releases of Arpida Ltd. (acquired by Evolva).

Data


26,368
Tech investments
From our Online Data Service
17,022
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 15€2.4MMaterials
Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 14€4.5MOther Software
Nov 14€4.7MBusiness applications
Nov 14€9.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.